Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables
Authors:
- 1 January 2017
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 11 (1) , 102-109
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk PreventionAmerican Journal of Therapeutics, 2016
- Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literatureAtherosclerosis, 2015
- Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular DiseaseJACC, 2014
- Triglycerides and cardiovascular diseaseThe Lancet, 2014
- Postprandial lipemia as a cardiometabolic risk factorCurrent Medical Research and Opinion, 2014
- Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A reviewJournal of Clinical Lipidology, 2012
- Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-AnalysisCurrent Atherosclerosis Reports, 2011
- Triglycerides and Cardiovascular DiseaseCirculation, 2011
- Omega-3 fatty acids for the treatment of elevated triglyceridesClinical Lipidology, 2009
- Role of Prescription Omega‐3 Fatty Acids in the Treatment of HypertriglyceridemiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007